SmithKline Beecham

Pharmaceuticals

5 June 1997

DirectLine: 0181-913-4521

 

Fax Nuniber: 0181-913-4495

Dear Mr Medawar

Thank you for your letter dated 8 May 1997. I apologise for the delay in penning this response.

I do not believe that it will be constructive to enter into a correspondence of cynicism and sarcasm.

I am fully aware of the ABPI Guidelines on disclosure of information, and how it relates to health professionals, and my decision not to supply a member of the public with the information requested stands.

SmithKline Beecham strive to publish papers on all clinical studies conducted, and such publications are generally available.

Your letter, and indeed paper, allude to a conspiracy within medicine as a whole. Given the nature of regulation surrounding both the pharmaceutical industry and the provision of healthcare, I cannot agree that secrecy is an issue. Rather, regulations are in place to ensure appropriate dissemination of information.

Yours sincerely

Dr Mark Sampson MBChB MRCGP
Acting Medical Director
Research & Development Pharmaceuticals UK

CLICK HERE TO READ ON

Contents page
Correspondence with pharmaceutical companies